Impact of prior treatment on patients with relapsed multiple
myeloma treated with carfilzomib and dexamethasone vs
bortezomib and dexamethasone in the phase 3 ENDEAVOR study

J 2017

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT et. al.

Základní údaje

Originální název

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Autoři

Vydání

Leukemia, London, Nature Publishing Group, 2017, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.023

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/leu.2016.186

UT WoS

000394058700015

Klíčová slova anglicky

2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 3. 2018 16:59, Soňa Böhmová

Anotace

V originále

The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.

Citovat

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG a M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. London: Nature Publishing Group, 2017, roč. 31, č. 1, s. 115-122. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2016.186.

@article{1369191,
   author = {Moreau, P. and Joshua, D. and Chng, W.andJ. and Palumbo, A. and Goldschmidt, H. and Hájek, R. and Facon, T. and Ludwig, H. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosiñol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S. and Dimopoulos, M.A.},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1038/leu.2016.186},
   keywords = {2ND-GENERATION PROTEASOME INHIBITOR; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; RETREATMENT},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study},
   url = {http://dx.doi.org/10.1038/leu.2016.186},
   volume = {31},
   year = {2017}
}

TY  - JOUR
ID  - 1369191
AU  - Moreau, P. - Joshua, D. - Chng, W.-J. - Palumbo, A. - Goldschmidt, H. - Hájek, R. - Facon, T. - Ludwig, H. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosiñol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S. - Dimopoulos, M.A.
PY  - 2017
TI  - Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
JF  - Leukemia
VL  - 31
IS  - 1
SP  - 115-122
EP  - 115-122
PB  - Nature Publishing Group
SN  - 08876924
KW  - 2ND-GENERATION PROTEASOME INHIBITOR
KW  - STEM-CELL TRANSPLANTATION
KW  - LENALIDOMIDE MAINTENANCE
KW  - RETREATMENT
UR  - http://dx.doi.org/10.1038/leu.2016.186
L2  - http://dx.doi.org/10.1038/leu.2016.186
N2  - The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with greater than or equal to2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (greater than or equal to2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
ER  -

MOREAU, P., D. JOSHUA, W.-J. CHNG, A. PALUMBO, H. GOLDSCHMIDT, R. HÁJEK, T. FACON, H. LUDWIG, Luděk POUR, R. NIESVIZKY, A. ORIOL, L. ROSIÑOL, A. SUVOROV, G. GAIDANO, T. PIKA, K. WEISEL, V. GORANOVA-MARINOVA, H.H. GILLENWATER, N. MOHAMED, S. AGGARWAL, S. FENG a M.A. DIMOPOULOS. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. \textit{Leukemia}. London: Nature Publishing Group, 2017, roč.~31, č.~1, s.~115-122. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2016.186.

Podrobný výpis o publikaci